GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of ...

London: Pfizer recently achieved a significant legal victory by winning bid in a London court to invalidate two patents held ...

GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting: London, UK Wednesday, October 9, 2024, 14:0 ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

GSK said a dose of its RSV vaccine protected against illness over three years, according to new data presented at the CHEST ...

The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving ...

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

Tata Motors' British luxury car unit, Jaguar Land Rover (JLR), reported a three percent decline in retail sales to 1,03,108 ...

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...